• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Doxorubicin - Key patent, SPC, and data exclusivity expiry (44 country coverage) Product Image

Doxorubicin - Key patent, SPC, and data exclusivity expiry (44 country coverage)

  • Published: June 2013
  • GenericsWeb

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Doxorubicin
Doxorubicin indications: Breast cancer; Karposi's sarcoma; Ovarian cancer
Doxorubicin innovator: Pharmacia (Adriamycin, Doxorubicin Rapid, Pharmorubicin Rapid); Schering-Plough (Caelyx); Zeneus (Myocet); Pfizer (Adriamycin, Ellence); Ortho Biotech (Doxil); Bristol-Myers Squibb (Rubex)

Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of READ MORE >

Pharmacia (Adriamycin, Doxorubicin Rapid, Pharmorubicin Rapid); Schering-Plough (Caelyx); Zeneus (Myocet); Pfizer (Adriamycin, Ellence); Ortho Biotech (Doxil); Bristol-Myers Squibb (Rubex)

Format Properties
Electronic (Online Access) The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos